The Claim
In women, higher plasma copeptin levels are associated with an increased risk of type 2 diabetes, with a stronger association observed in those without impaired fasting glucose at baseline, yielding an adjusted odds ratio of 1.81 (95% CI 1.42–2.30).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Women with higher levels of copeptin in their blood have a greater risk of developing type 2 diabetes, especially if their blood sugar levels were normal at the start of the study.
See the scientific wording
The association between plasma copeptin and type 2 diabetes risk in women is stronger in those without impaired fasting glucose at baseline, with an adjusted odds ratio of 1.81 (95% CI 1.42–2.30), suggesting copeptin may be particularly useful for identifying women at risk before glucose abnormalities develop.
When stress signals increase, the brain releases a hormone that tells the liver to make more sugar and the pancreas to change how it releases insulin. In women, this system is more sensitive, so even small increases in the hormone cause bigger changes in blood sugar, leading to diabetes before blood sugar levels officially become abnormal.
What the research says
1 studyIn women with normal blood sugar, higher levels of a substance called copeptin in the blood were linked to a greater chance of developing type 2 diabetes later — meaning it could help spot those at risk before their blood sugar starts to rise.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.